Publications by authors named "Miler Andres Cuellar-Rivas"
Introduction: The COVID-19 pandemic is a great burden worldwide, but its impact on patients with genitourinary cancer (GUC) is poorly characterized. This study aimed to characterize the clinical features and evolution of GUC patients affected by COVID-19 in Spain.
Patients And Methods: SOGUG-COVID-19 was an observational ambispective non-interventional study that recruited patients with SARS-CoV-2 infection who had been treated for GUC in 32 Spanish hospitals.
Article Synopsis
- Advanced penile squamous cell carcinoma (PSCC) has poor outcomes, and patients often have limited treatment options, but PD-L1 expression is a potential target for immunotherapy, like retifanlimab.
- In the ORPHEUS trial, 18 previously untreated patients received retifanlimab, showing an objective response rate of 16.7% and a median duration of response of 3.3 months, with some patients experiencing clinical benefit.
- The results indicate that retifanlimab has potential activity against advanced PSCC with manageable safety, but the small sample size suggests the need for further studies to confirm these findings.